Published in J Atten Disord on April 09, 2008
Advances in understanding and treating ADHD. BMC Med (2011) 1.21
A clinical overview of sleep and attention-deficit/hyperactivity disorder in children and adolescents. J Can Acad Child Adolesc Psychiatry (2009) 0.96
ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics (2012) 0.95
Effect of methylphenidate on sleep parameters in children with ADHD. Psychiatry Investig (2012) 0.84
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct (2009) 0.83
A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs (2014) 0.78
Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS Drugs (2014) 0.76
Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr (2016) 0.75
Comorbidity and confounding factors in attention-deficit/hyperactivity disorder and sleep disorders in children. Psychol Res Behav Manag (2011) 0.75
Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol (2016) 0.75
To sleep or not to sleep: a systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2013) 0.75
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. CNS Drugs (2017) 0.75
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (2008) 20.68
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry (2009) 6.71
Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction (2008) 4.46
Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2005) 3.79
A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry (2006) 3.68
Geographic variation in the prevalence of attention-deficit/hyperactivity disorder: the sunny perspective. Biol Psychiatry (2013) 3.47
A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry (2004) 3.44
3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry (2007) 3.33
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2011) 2.72
Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol (2006) 2.64
Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry (2004) 2.63
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet (2006) 2.53
Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2007) 2.49
Three potential susceptibility loci shown by a genome-wide scan for regions influencing the age at onset of mania. Am J Psychiatry (2004) 2.40
Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet (2005) 2.34
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics (2009) 2.13
Growing evidence to support early intervention in early onset bipolar disorder. Aust N Z J Psychiatry (2007) 2.09
Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet (2005) 2.05
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder? J Consult Clin Psychol (2005) 2.03
Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol (2003) 2.02
Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry (2002) 2.01
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol (2007) 1.98
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry (2007) 1.98
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 1.97
Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians. Psychol Bull (2006) 1.92
Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry (2007) 1.82
Review and meta-analysis of the phenomenology and clinical characteristics of mania in children and adolescents. Bipolar Disord (2005) 1.78
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry (2007) 1.75
Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr (2005) 1.74
Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry (2006) 1.71
A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2008) 1.70
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull (2007) 1.69
Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry (2005) 1.69
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med (2012) 1.67
Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study. J Clin Psychiatry (2010) 1.67
Validity of the autism diagnostic interview-revised. Am J Ment Retard (2006) 1.66
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry (2009) 1.66
Validation of the Mood Disorder Questionnaire for bipolar disorders in adolescents. J Clin Psychiatry (2006) 1.64
The services for children and adolescents-parent interview: development and performance characteristics. J Am Acad Child Adolesc Psychiatry (2004) 1.64
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry (2003) 1.63
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry (2006) 1.61
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry (2002) 1.60
Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis. Bipolar Disord (2008) 1.59
Gender differences in criminality: bipolar disorder with co-occurring substance abuse. J Am Acad Psychiatry Law (2005) 1.59
Developing a 10-item mania scale from the Parent General Behavior Inventory for children and adolescents. J Clin Psychiatry (2008) 1.58
Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. Bipolar Disord (2005) 1.56
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet (2005) 1.50
Toward an evidence-based assessment of pediatric bipolar disorder. J Clin Child Adolesc Psychol (2005) 1.50
Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. J Abnorm Child Psychol (2009) 1.48
Comparing the diagnostic accuracy of six potential screening instruments for bipolar disorder in youths aged 5 to 17 years. J Am Acad Child Adolesc Psychiatry (2004) 1.48
Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry (2002) 1.48
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry (2007) 1.48
Longitudinal Assessment of Manic Symptoms (LAMS) study: background, design, and initial screening results. J Clin Psychiatry (2010) 1.47
Guns, adolescents, and mental illness. Am J Psychiatry (2008) 1.46
Internal consistency and associated characteristics of informant discrepancies in clinic referred youths age 11 to 17 years. J Clin Child Adolesc Psychol (2011) 1.46
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord (2008) 1.46
Early onset bipolar disorder: possible linkage to chromosome 9q34. Bipolar Disord (2006) 1.43
Self-perceptions of competence in children with ADHD and comparison children. J Consult Clin Psychol (2004) 1.43
Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol (2005) 1.41
The genetics of pediatric-onset bipolar disorder. Biol Psychiatry (2003) 1.40
Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry (2004) 1.40
Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol (2006) 1.40
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry (2003) 1.39
International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol (2004) 1.38
Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil (2005) 1.38
Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet (2004) 1.37
Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry (2007) 1.36
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2004) 1.34
Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry (2006) 1.34
Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol (2010) 1.31
Reliability of the services for children and adolescents-parent interview. J Am Acad Child Adolesc Psychiatry (2004) 1.31
Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry (2006) 1.31
A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 1.28
Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. Addict Behav (2009) 1.27
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord (2008) 1.27
Assessing Homework Problems in Children with ADHD: Validation of a Parent-Report Measure and Evaluation of Homework Performance Patterns. School Ment Health (2010) 1.27
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry (2008) 1.27
Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry (2004) 1.27
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry (2005) 1.26
Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav (2009) 1.26
Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. J Clin Child Adolesc Psychol (2002) 1.26
Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull (2006) 1.26
Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J Clin Psychiatry (2011) 1.25
Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol (2005) 1.24
Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry (2005) 1.24
The transition to middle school is associated with changes in the developmental trajectory of ADHD symptomatology in young adolescents with ADHD. J Clin Child Adolesc Psychol (2008) 1.24
Examining the proposed disruptive mood dysregulation disorder diagnosis in children in the Longitudinal Assessment of Manic Symptoms study. J Clin Psychiatry (2012) 1.23
Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry (2002) 1.23